Table 2.
Treatment | End Points | 1 wk | 2 wk | 4 wk |
PBS | ||||
CVX-045 (30 mg/kg 1x/wk) | Apoptosis | * | † | |
MVD | † | |||
Bevacizumab (5 mg/kg 2x/wk) | Apoptosis | * | † | |
MVD | † | † |
Apoptosis and MVD were measured as described. Statistical differences were determined using ANOVA with a Bonferroni post test to compare test samples to time-matched PBS-treated controls. MVD indicates microvessel density.
P < .05.
P < .001.